Targeted Non-Small Cell Lung Cancer | Proceedings from a live event held adjunct to the 2021 ASCO Annual Meeting

published 3 weeks ago by Dr Neil Love

Featuring perspectives from Prof Solange Peters and Drs Zofia Piotrowska and Gregory J Riely, including the following topics: Current and Future Treatment of Non-Small Cell Lung Cancer (NSCLC) with Targetable Mutations, Including ALK and ROS1 Introduction: Targeted treatment in the adjuvant setting (0:00) Case: A man in his late 60s with metastatic adenosquamous carcinoma of the lung — PD-L1 >95%, ROS1 rearrangement — Margaret Deutsch, MD (11:55) Case: A woman in her mid-70s with metastatic adenocarcinoma of the lung and cancer in the right breast — TMB 14 mut/Mb, ALK mutation — Raymond Lobins, DO (19:15) Management Strategies for Patients with NSCLC with RET Fusions or MET Alterations Case: A woman in her early 60s with metastatic adenocarcinoma of the lung — PD-L1 0%, RET KIF5B fusion — Mohamed K Mohamed, MD, PhD (24:40) Key Data Guiding the Management of Metastatic NSCLC with EGFR Mutations Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung — PD-L1 60%, EGFR exon 19 deletion — Gigi Chen, MD (29:15) Case: A man in his early 70s with metastatic NSCLC — EGFR L858R mutation — Maria Regina Flores, MD (36:53) Therapeutic Approaches for Patients with NSCLC with HER2 or KRAS Mutations Case: A woman in her early 60s with recurrent metastatic adenocarcinoma of the lung — HER2 mutation — Dr Lobins (43:20) Case: A woman in her mid-40s with metastatic adenocarcinoma of the lung — KRAS G12C mutation — Sulfi Ibrahim, MD (51:03) CME information and select publications  

more episodes from Research To Practice | Oncology Videos